Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Uppsala – page 22

335 clinical trials in Uppsala, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Uppsala at a glance
335
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

335 trials in Uppsala

Open in trial search

Renal transplant+1

Not recruiting

Study of Tocilizumab Treatment for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Vaestra Goetalandsregionen

Lupus nephritis+1

Not recruiting

Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Transitional cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Hypercholesterolaemia

Not recruiting

Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Ovarian cancer stage III

Not recruiting

Study on the Effect of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Stage III Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Uppsala

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic breast cancer and prostate cancer treatments, including targeted therapies and novel drug combinations.

  • Advanced breast cancer treatments
  • Prostate cancer therapies
  • Colorectal cancer studies

Particular emphasis on HER2-positive breast cancer imaging and treatment optimization.

02 Metabolic Disorders

Research initiatives targeting obesity management and metabolic health, with studies evaluating new therapeutic approaches for weight management in both adults and adolescents.

  • Weight management treatments
  • Adolescent obesity studies
  • Metabolic health interventions

Focus on innovative drug combinations and long-term effectiveness studies.

03 Cardiovascular and Renal Studies

Comprehensive research on heart failure prevention and chronic kidney disease management, investigating new therapeutic combinations.

  • Heart failure prevention
  • Kidney disease treatments
  • Hypertension management

Emphasis on combination therapies and preventive approaches.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.